【醫(yī)學(xué)課件】專家談萬絡(luò)退出全球市場ppt課件-展示頁
2024-10-28 06:50本頁面
【正文】 ertising Merck amp。 Co refused to conduct the necessary oute studies Topol Company launched three studies looking at noncardiovascular outes, but measuring cardiovascular events Thumbs up/Thumbs down – October 2021 APPROVE trial One studyAdenomatous Polyp Prevention on VIOXX (APPROVE)tested rofecoxib 25 mg vs placebo in the prevention of the recurrence of colorectal polyps in 2600 patients with a history of colorectal adenoma RESULTS ? Study showed an increased relative risk for MI and stroke with rofecoxib, which became evident after 18 months of treatment ? 45 confirmed events in the rofecoxib group (%) vs 25 in the placebo group (%) Thumbs up/Thumbs down – October 2021 VIOXX: Risk and benefit Rofecoxib withdrawn September 30, 2021 This is just one of many types of drugs that are given to people for years with absolutely no understanding of what the chronic balance of risk and benefit is because it39。s thoughts In the VIOXX Gastrointestinal Outes Research (VIGOR) studywhich indicated an increased risk of cardiovascular events with rofecoxib vs naproxencurves diverged at 30 days You can get an MI or stroke from one Vioxx pill. Topol Thumbs up/Thumbs down – October 2021 VIOXX: Should have acted earlier There was the potential for Merck and the FDA to do the right thing much earlier ? Merck defended past studies as flawed and the drug as cardioprotective ? Directtoconsumer advertising fueled the inductio
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1